Swift Implementation of Tailored Enterprise Software Solutions

技术

分析与建模 - 数据即服务
分析与建模 - 实时分析

适用行业

药品

适用功能

产品研发
质量保证

用例

质量预测分析
根因分析与诊断

服务

数据科学服务
系统集成

挑战

Bayer Pharmaceuticals was facing several challenges in their lab. They were developing new methods to characterize novel classes of biopharmaceuticals, which was compounded by the novel nature of the analytes, for which no established MS-based protocols were available. Interpreting results and iteratively optimizing experimental and analytical methods for such molecules required a significant amount of area expertise in MS-based characterization of biotherapeutics. They also needed to deliver productive output in a timely manner to meet the needs of their internal customers involved in time-critical projects and maximize Bayer’s return on investment in new infrastructure. The novel nature of their analytes and protocols and the limitations of the available software made interpretation of results far from straightforward. When troubleshooting a complex process issue, it was extremely helpful to have not only domain expertise, but also to have a comprehensive and unbiased overview of all data at all stages of processing. Any solution that they implemented had to be scalable and able to handle high sample throughputs. Using the available software, data processing and the production of targeted reports were laborious and time-consuming processes that required frequent manual interventions.

关于客户

Bayer Pharmaceuticals is a company that focuses on researching, developing, manufacturing and supplying specialty-focused innovative medicines that provide significant clinical benefit and value. The company has been a customer since 2006. Comprehensive characterization and efficient quality monitoring are key factors to ensure safety and efficacy of novel biotherapeutics while reducing their development costs. Providing information at the molecular-level and delivering high analytical throughput, mass spectrometry is increasingly being used across the biopharma industry to supplement and replace established analytical techniques that cannot address the inherent structural complexity of biotherapeutics. To keep pace with the increasing demand for MS-based analyses, Bayer expanded their lab’s capacity and capabilities by acquiring two new instruments and developing novel protocols for intact mass analysis and peptide mapping.

解决方案

Bayer Pharmaceuticals established a partnership with Genedata to overcome their challenges. Genedata began with their scientific consultants visiting Bayer's site and carrying out a comprehensive analysis of their entire MS data acquisition and processing workflow. Through careful consultation with Bayer's scientists, Genedata identified their current and future needs for an MS data processing platform. Working in close collaboration with Genedata experts, Bayer evaluated the results, designed an optimized end-to-end MS analysis strategy—from sample preparation to result reporting—and planned an implementation timeline that addressed and prioritized their needs. During the implementation phase, Genedata consultants provided extensive on-site training, regularly visited Bayer's site to monitor progress, and reacted very quickly to all their requests for support. After successfully applying the intact mass analysis workflow in their lab, Bayer was able to quickly develop and implement additional solutions for peptide mapping and oligonucleotide analysis, and they are currently developing more workflows.

运营影响

Fast implementation of a productive platform that addresses Bayer's specific needs
A single-software solution for all MS-based biopharma applications
A trusted partnership with the leading provider of enterprise software solutions for biopharma